Số 78 - 2025 (English)

9 Tháng 6, 2025

Bài báo nghiên cứu gốc

RESULTS OF FIRST-LINE CHEMOTHERAPY IN RECURRENT/METASTATIC NON-SMALL CELL LUNG CANCER PATIENTS HARBORING EGFR EXON 20 INSERTION MUTATIONS

Tác giả: Trần Thị Hậu, Đỗ Hùng Kiên, Đào Minh Thế

DOI: https://doi.org/10.70755/vnjo.2025.78.6

Số 78 - 2025 (English) | Tạp Chí Ung Thư Học Việt Nam

+ Thông tin tác giả và bài nghiên cứu

Tóm tắt

ABSTRACT

Introduction: Non-small cell lung cancer (NSCLC) with exon 20 insertion mutations accounts for 4-10% of all NSCLC patients with EGFR mutations. The primary treatment for NSCLC patients with recurrent metastatic EGFR exon 20 insertion mutations remains platinum-based doublet chemotherapy. However, there are very few studies in Vietnam evaluating the effectiveness of this treatment. Therefore, this study was conducted to evaluate the effectiveness of this therapy in the mentioned patient group.

Subjects and Methods: This is a retrospective cross-sectional descriptive study on 36 NSCLC patients with recurrent metastatic EGFR exon 20 insertion mutations treated with platinum-based doublet chemotherapy from January 2019 to June 2024 at K Hospital to evaluate treatment outcomes and adverse effects of the regimen in this patient group.

Results: The response rate of the regimen was 25%, and the disease control rate was 66.7%. The median progression-free survival (PFS) was 7.0 months. The median overall survival (OS) was 17.6 months. The majority of patients experienced at least one adverse effect, accounting for 80.6%. The most common adverse effects were neutropenia (in 58% of patients), peripheral neuropathy (44%), anemia (48%), and nausea (42%). The most common grade 3 or higher adverse effects were neutropenia (25%), thrombocytopenia (6%), and anemia (8%). Dose reductions and drug discontinuations due to adverse effects were reported in 17% and 8% of patients, respectively.

Conclusion: Platinum-based doublet chemotherapy as the first-line treatment for NSCLC patients with recurrent metastatic disease is an effective treatment with manageable toxicity.

Từ khóa: Non-small cell lung cancer, EGFR exon 20 insertion, platinum-based doublet chemotherapy

Abstract

.

Keywords: .

Bạn không có quyền truy cập vào bài viết này!

Hãy đăng nhập để xem

Nếu bạn chưa có tài khoản vui lòng? Đăng ký

Đăng nhập

Online ISSN

1859-400X

Print ISSN

1859-400X